| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447137 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
The combination of Myocet®, docetaxel and trastuzumab is safe and shows promising activity as first-line treatment of HER-2-positive MBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
D. Amadori, C. Milandri, G. Comella, S. Saracchini, S. Salvagni, C. Barone, R. Bordonaro, V. Gebbia, A. Barbato, P. Serra, D. Gattuso, O. Nanni, B. Baconnet, G. Gasparini,